Modulation of retroviral restriction and proteasorne inhibitor-resistant turnover by changes in the TRIM5α B-Box 2 domain

An intact B-box 2 domain is essential for the antiretroviral activity of TRIM5 alpha. We modeled the structure of the B-box 2 domain of TRIM5 alpha based on the existing three-dimensional structure of the B-box 2 domain of human TRIM29. Using this model, we altered the residues predicted to be exposed on the surface of this globular structure. Most of the alanine substitutions in these residues exerted little effect on the antiretroviral activity of human TRIM5c alpha(hu). or rhesus monkey TRIM5C alpha(rh). However, alteration of arginine 119 of TRIM5 alpha(hu). or the corresponding arginine 121 of TRIM5 alpha(rh), diminished the abilities of the proteins to restrict retroviral infection without affecting trimerization or recognition of the viral capsid. The abilities of these functionally defective TRIM5 alpha proteins to accelerate the uncoating of the targeted retroviral capsid were abolished. Removal of the positively charged side chain from B-box 2 arginines 119/120/121 resulted in diminished proteasome-independent turnover of TRIM5 alpha and the related restriction factor TRIMCyp. However, testing of an array of mutants revealed that the rapid turnover and retroviral restriction functions of this B-box 2 region are separable.